• Current Studies

    (Updated March 2020)

    ACCRF has compiled a list of clinical trials for ACC patients with progressive disease to consider. This website is updated periodically, but may not list all the pertinent and available trials. Patients may search on their own for recruiting ACC clinical trials on the ClinicalTrials.gov website.

    The clinical trials are broken down into three categories.

    • The first table lists studies that are recruiting any and all ACC patients (usually phase II clinical trials).
    • The second table lists studies appropriate for ACC patients whose tumors have been profiled and found to have activating alterations in NOTCH genes (either phase I or II clinical trials).
    • The third table includes clinical trials that incorporate tumor profiling prior to selecting a drug (“basket studies”).

    In all cases, patients should consult with their physicians to discuss the appropriate course of action.

    Not all clinical trials have similarly strong scientific rationales for why the drugs should be effective in ACC. The most promising studies will involve drugs that (1) target the known mechanisms of action that drive ACC progression, (2) demonstrate activity in preclinical models of ACC, and (3) have reports of clinical benefit in an ACC patient from a case study or Phase I clinical trial. To assist patients in appraising each clinical trial, we indicate whether the evidence supporting the scientific rationale is very strong, solid or fair. This assessment is based on the underlying scientific rationale, and does not mean that a particular trial is better or worse for any given patient, and should be considered along with his or her physician.

    The table below lists clinical trials that currently are recruiting ACC patients in particular or salivary gland cancer patients. Unless otherwise noted, these studies are for only ACC patients with recurrent or metastatic disease. Links are provided to descriptions of the drugs as well as the www.ClinicalTrials.gov summary of each study.

    Clinical Trials for All ACC Patients

    Compound Targets Sponsor Locations Scientific Rationale Info Link Contact
    Rivoceranib (Apatinib) VEGFR Elevar Therapeutics Seoul, Korea
    Boston, MA, USA
    Denver, CO, USA
    San Francisco, CA, USA
    Very Strong View Steven Norton, PhD
    1-801-303-7440 ext 275
    steven.norton@elevartherapeutics.com
    Axitinib and Avelumab VEGFR, PDGFR, KIT and PD-L1 Immunotherapy MD Anderson Houston, TX, USA Strong View Renata Ferrarotto, MD
    1-713-792-6363
    APG-115 with or without Carboplatin MDM2 University of Michigan Ann Arbor, MI, USA Solid View Paul L Swiecicki, MD 1-734-647-1017 pswiecic@med.umich.edu
    Ryan Drzewicki ryandrze@med.umich.edu
    Pembrolizumab and Docetaxel PD-1 Immunotherapy University of Chicago Chicago, IL, USA Solid View Alexander Pearson, MD, PhD
    apearson5@medicine.bsd.uchicago.edu
    Chidamide and Cisplatin HDAC Fudan University Shanghai, China Solid View Kai Xue, MD
    021-64175590
    xuekaishanghai@126.com
    Chidamide HDAC Chinese Academy of Medical Sciences Beijing, China Fair View Mei Dong
    +86-10-87788130
    Dongmei030224@163.com
    Nivolumab and Ipilimumab and Radiation PD-1
    and CTLA-4
    Immunotherapy
    University of Washington Seattle, WA, USA Fair View Susan Masterson
    1-206-606-7445
    smasters@seattlecca.org
    Apatinib and Proton Radiation (for inoperable or residual ACC) VEGFR Shanghai Proton and Heavy Ion Center Shanghai, China Strong View Lin Kong, MD lin.kong@sphic.org.cn
    Jiyi Hu, MD jiyi.hu@sphic.org.cn
    CV8102 (for advanced inoperable ACC of head & neck that is superficial and readily-accessible) TLR7/8 CureVac Germany (multiple sites) Solid View Thomas Eigentler, Prof. Dr.
    thomas.eigentler@med.uni-tuebingen.de

    Approximately 25% of metastatic ACC patients have tumors with activating alterations in the NOTCH pathway (primarily in the NOTCH1 gene). These tumors behave more aggressively. Patients for whom tumor profiling has identified a NOTCH pathway alteration may wish to discuss the following studies with their physicians:

    Clinical Trials for ACC Patients with Activating NOTCH Alterations

    Compound Targets Sponsor Locations Scientific Rationale Info Link Contact
    AL101 NOTCH Ayala Pharmaceuticals Calgary, Alberta, Canada
    Hamilton, Ontario, Canada
    London, Ontario, Canada
    Copenhagen, Denmark
    Bordeaux, France
    Lyon, France
    Villejuif, France
    Barcelona, Spain
    Madrid, Spain
    Manchester, UK
    Boston, MA, USA
    Houston, TX, USA
    Miami, FL, USA
    New York, NY, USA
    Tampa, FL, USA
    Seattle, WA, USA
    Strong View clinicaltrials@ayalapharma.com
    CB-103 NOTCH Cellestia Pharmaceuticals Amsterdam, Netherlands
    Maastricht, Netherlands
    Utrecht, Netherlands
    Barcelona, Spain
    Madrid, Spain
    Bellinzona, Switzerland
    Strong View Pavel Pisa, MD
    pavel.pisa@cellestia.com

    Historically, clinical trials involved only one or two treatments. Some newer trials are incorporating tumor profiling to direct patients to many more potential treatments within the same study. These “basket trials” try to match targeted drugs to genomic alterations in each patient’s particular tumor. Some of these trials profile the patient’s tumor as party of the study (NCI-MATCH) while others will suggest treatment decisions based on existing tumor profiling reports (ASCO TAPUR). The clinical trials listed below are not specifically for ACC patients, but may be worth considering in consultation with a knowledgeable physician.

    “Basket” Clinical Trials Incorporating Tumor Profiling

    Compound Targets Sponsor Locations Scientific Rationale Info Link Contact
    NCI-MATCH Multiple targets National Cancer Institute Over 1,000 locations in USA Solid View View Info Link for details on each site
    ASCO TAPUR Multiple targets American Society of Clinical Oncology Over 20 locations in USA Solid View Pam Mangat, MS
    pam.mangat@asco.org
    Download Selected Clinical Trials – Currently Open (Updated March 2020)